In Silico Comparison Between Metoprolol Succinate and Bisoprolol on 24-Hour Systolic Blood Pressures by unknown
ORIGINAL RESEARCH ARTICLE
In Silico Comparison Between Metoprolol Succinate
and Bisoprolol on 24-Hour Systolic Blood Pressures
Sven-Olof Jansson • Anders E. Malm •
Torbjo¨rn Lundstro¨m
Published online: 9 December 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Objective To compare the effects of bisoprolol and
metoprolol CR/ZOK (metoprolol succinate controlled
release) on systolic blood pressure (bpsys) over a 24-h
period in an in silico model.
Methods On the basis of the observed data from ambula-
tory blood pressure measurements (ABPM), a model with an
appropriate distribution and correlation structure was
derived for simulation of 24-h bpsys patterns during treatment
with commonly studied doses, assumed to be equipotent, of
bisoprolol and metoprolol CR/ZOK. Input into the simula-
tions was aligned with the available data on the diurnal
efficacy and pharmacology profiles of these substances. The
validity of the model was tested in a bootstrap model.
Results The simulation model reproduced the observed
data with high congruence (p = 1.0). The mean 24-h bpsys
values did not significantly differ between the two simu-
lated groups (estimated overall change in bpsys [Dbpsys] for
metoprolol versus bisoprolol = 2.7 mmHg [95 % confi-
dence interval -0.3 to 5.7 mmHg]; p = 0.08). There were
clear diurnal differences, with bisoprolol being more
effective earlier and metoprolol CR/ZOK being more
effective later in the 24-h day. A validity test with 100
repeated samples gave an overall mean group difference of
1.4 ± 3.59 mmHg (p = 0.63 relative to simulation).
Conclusion In a robust model for the simulation of 24-h
ABPM, comparisons between bisoprolol and metoprolol
CR/ZOK indicate a comparable overall blood pressure-
lowering effect but different diurnal patterns, consistent
with the pharmacokinetics of the two drugs. This difference
may be of clinical relevance, given the recognized diurnal
pattern of cardiovascular events.
Key Points
To provide maximal efficacy in preventing
cardiovascular events, b-blockers should be present
at sufficient strength over the entire 24-h day.
This modeling study showed that bisoprolol and
metoprolol succinate provide comparable overall
blood pressure-lowering activity.
However, there are differences between the two
drugs in the diurnal pattern of their antihypertensive
effects, with metoprolol succinate providing greater
efficacy toward the end of the 24-h day.
1 Introduction
Cardiovascular (CV) events, such as acute coronary syn-
dromes, stroke, and sudden cardiac death, show time-
varying incidence ranging over the 24-h day and according
to the season of the year. The reasons for this variation are
not fully understood, but it is known that the adrenergic
neurohormonal system is one important factor [1, 2].
Consequently, it is believed that the prophylactic effect
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exerted by b-blocking drugs on the incidence of CV events
can be explained by these drugs’ anti-adrenergic effects [3,
4]. It also follows that to be maximally effective, the b-
receptor blocking effect should be present at sufficient
strength over the entire 24-h day.
In recognition of the advantages of improved compli-
ance and the need for day-long efficacy, major b-blocker
drugs have been developed for once-daily intake. Modifi-
cation to prolong the elimination of a drug is one approach
to make once-daily administration feasible. Another means
toward this is to extend the time of absorption. Bisoprolol
fumarate attains once-daily dosing because of slow recep-
tor dissociation, while metoprolol CR/ZOK (metoprolol
succinate) exemplifies the controlled-release path for once-
daily dosing [5, 6].
Metoprolol CR/ZOK and bisoprolol are both (with vari-
ous national limitations) approved for control of hyperten-
sion, ischaemic heart disease, heart failure, and reduction of
the risk of CV events associated with these conditions [7, 8].
However, because of their differing pharmacokinetic pro-
files, there may be diurnal differences in cardioprotective
effects between the two drugs. To further explore this pos-
sibility, an in silico model of 24-h blood pressures was
developed, making use of published data.
2 Methodology
2.1 Data Extraction
Data on the pharmacokinetic and blood pressure effects of
bisoprolol were obtained as summary data from the pub-
lished literature [6, 9–18]. Corresponding published infor-
mation on metoprolol CR/ZOK was available on the
individual subject level [5, 19]. Ambulatory blood pressure
measurement (ABPM) values for untreated hypertensive
patients were also obtained on the individual level.
The Ovid Medline and Embase databases were queried
for publications in the English language with abstracts on
metoprolol and bisoprolol, using both substance names and
product labels. Papers with abstracts informing on blood
pressure, ABPM, or pharmacokinetics were further studied,
and those providing 24-h data in numerical formats were
used. No publication with results based on admitted
patients was included.
All data from clinical trials were obtained from studies
that had obtained ethics approval.
2.2 Simulation
In an initial step, hourly systolic blood pressure (bpsys)
values for 266 untreated hypertensive subjects (aged
55 ± 9.4 years; 103 of whom were female) were derived
as the means of three measurements per hour for a
24-h day (from 1000 hours to 1000 hours).
As a second step, corresponding mean hourly bpsys
values were calculated and adjusted to the plasma con-
centration curves for bisoprolol (as published) and meto-
prolol CR/ZOK, on the basis of a steady-state situation,
with dosing being simultaneous with the start of the blood
pressure recording.
Thirdly, two sets of random data for bisoprolol and
metoprolol CR/ZOK, respectively, were generated, repre-
senting hourly bpsys values in 266 subjects, and aligned to
the calculated mean hourly values. This operation was
based on bpsys values following a normal distribution
(truncated to [75 to \210 mmHg), constant variance over
the 24 time points, and expected individual bpsys value as
the means of the preceding individual value and the group
average values for the current time point.
2.2.1 Simulation Model
A linear mixed model of repeated measurements with an
autoregressive correlation structure with moving averages
was used to obtain predicted values and covariance from
the ABPM data on the 266 untreated patients. These values
were then used to simulate individual data from a bivariate
normal distribution. Using the same regression model and
covariance, simulated individual 24-h ABPM bpsys values
were built from the data created for the bisoprolol and
metoprolol CR/ZOK data sets, respectively. Published
information on variance of bpsys is generally based on
office or summary recordings, and is smaller than the
observations of individual time points in ABPM [13]. For
this reason, and on the basis of the available ABPM source
data, the standard deviation (SD) of the simulated values
was expanded by &4 mmHg.
2.3 Statistics
Summary results are presented as means ± SDs. Estimates
are given with 95 % confidence intervals, and a p-value of
\0.05 is taken as statistically significant. A linear mixed
model was employed to test differences between groups in
bpsys by time point. All statistical operations were done
with R 2.15.1 software (R Foundation for Statistical
Computing, Vienna, Austria; http://www.R-project.org).
3 Results
Demographic data and baseline average 24-h bpsys values
were congruent between the observed and published data.
The distribution of individual observed hourly bpsys values
appeared to be random (Fig. 1a).
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Validity testing of the model through repeated sampling
showed consistency over 100 random samples of 64 cros-
sed cases, with normally distributed p values for the overall
difference (p = 0.6) in the drug group effect, as well as for
the drug group by time point variable.
Distribution of hourly observed and simulated blood
pressures are presented in Table 1. The mean bpsys ± SD
values for the observed data were 146.2 ± 19.37 mmHg,
with an intra-individual SD of ±14.57. The mean ± inter-
and intra-individual SDs for the simulated baseline bpsys
values were 146.6 ± 22.86 and ± 15.03 mmHg,
respectively.
Figures 1 and 2 give a graphical display of the mean and
individual bpsys values for the observed baseline, simulated
baseline, and simulation of the two drug groups. The
broader distribution seen for bpsys obtained in the simula-
tion is also seen in the wider SDs.
Estimates of the change in bpsys (Dbpsys) for bisoprolol,
and for metoprolol CR/ZOK versus bisoprolol, are pre-
sented in Table 2 and Fig. 2. The mean 24-h bpsys values
were 128 ± 18.7 and 128 ± 18.0 mmHg (p [ 0.1) for the
simulated bisoprolol and metoprolol data, respectively. The
estimated overall difference between the two groups, when
controlled for the time effect, was 2.7 mmHg (95 % con-
fidence interval -0.3 to 5.7 mmHg).
The data for bisoprolol display a bimodal pattern, and
those for metoprolol CR/ZOK display a unimodal one
(Fig. 2). Plasma concentration curves for the two drugs are
presented in Fig. 3. Temporal differences in blood pres-
sure-lowering effects are seen, with bisoprolol being more
effective around its maximum plasma concentration, and
metoprolol CR/ZOK being more effective during the latter
two thirds of the 24-h day (Fig. 4, lower part, showing
metoprolol Dbpsys relative to bisoprolol Dbpsys).
Fig. 1 Mean and individual
observed and simulated baseline
systolic blood pressure (bpsys)
values. a Observed untreated
bpsys by subject and time of day
(hours). b Simulation of
untreated bpsys by subject and
time of day (hours)
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The overall group effect and effects by time point were
all within the range of the estimates of the 100 repeat
samples.
4 Discussion
In a robust model for simulation of 24-h ABPM, diurnal
differences in reduction of bpsys were demonstrated in the
comparison of bisoprolol and metoprolol CR/ZOK, though
the average blood pressure reductions were the same for
the two groups. The demonstrated temporal discrepancies
indicate the potential for differences in the impact on the
prevention of CV events and the risk of adverse effects
between the two treatments.
The exact mechanism by which b-blockers reduce blood
pressure is not known. It is, however, obvious that it is
caused by interference with the adrenergic system and the
antagonistic effect these drugs have on the b1-receptors.
Thus, the effects of b-blockers are dependent on the degree
of receptor antagonism, which, in turn, ultimately depends
on pharmacokinetic properties.
The characteristic pharmacokinetic properties of biso-
prolol are rapid absorption and, as consequence of delayed
receptor dissociation, protracted elimination [6, 14–18].
These two properties are well reflected in the effects of the
drug, with an early peak corresponding to the maximal
concentration and immediate uptake, followed by a gradual
tapering off until the next dose.
The pharmacokinetics of metoprolol CR/ZOK are
dominated by a protracted uptake period extending over
[10 h and (in comparison with bisoprolol) rapid elimina-
tion, with the net result of a more flat plasma concentration
curve and a less varying effect profile [5, 19]. Thus, when
compared with bisoprolol, metoprolol CR/ZOK is likely to
have a temporally less varying blood pressure-lowering
effect over the 24-h day. The average 24-h effect will be
the same for the two compounds, with bisoprolol being
more effective during the initial hours after drug intake and
metoprolol CR/ZOK showing a greater impact during the
latter part of the dose interval [20, 21].
The predilection of CV events to occur during late night
and early morning periods makes it attractive for a b-
blocker drug to have an effect during those hours, and is an
Table 1 Observed and
simulated systolic blood
pressure (bpsys) values,
expressed as means ± standard
deviations
Time of day (hours) Observed (mmHg) Simulation (mmHg)
Baseline Baseline Bisoprolol Metoprolol
10 158.2 ± 16.97 159.6 ± 22.32 133.4 ± 19.11 136.1 ± 18.04
11 155.2 ± 15.80 156.4 ± 21.72 129.3 ± 18.33 134.0 ± 19.24
12 155.6 ± 16.27 157.0 ± 21.93 128.7 ± 17.67 135.3 ± 18.27
13 152.3 ± 16.96 153.2 ± 22.07 127.2 ± 17.78 131.1 ± 16.87
14 151.1 ± 16.24 152.2 ± 21.82 124.5 ± 16.09 131.0 ± 17.90
15 152.3 ± 16.15 154.3 ± 22.53 128.8 ± 18.44 130.2 ± 16.64
16 154.0 ± 16.60 155.9 ± 20.54 128.5 ± 18.2 128.4 ± 17.33
17 154.5 ± 17.10 155.6 ± 20.78 129.0 ± 19.08 130.6 ± 18.12
18 154.9 ± 17.46 155.8 ± 21.81 131.0 ± 19.78 126.6 ± 18.23
19 154.8 ± 16.76 154.9 ± 22.25 129.9 ± 18.00 127.3 ± 17.44
20 152.4 ± 16.98 152.3 ± 22.34 128.6 ± 18.61 128.1 ± 15.61
21 148.8 ± 17.79 148.1 ± 21.73 126.4 ± 18.57 126.5 ± 16.10
22 145.9 ± 18.14 145.7 ± 20.16 124.7 ± 17.50 125.0 ± 16.61
23 139.8 ± 18.20 140.1 ± 19.93 124.0 ± 17.82 123.7 ± 16.79
00 135.4 ± 17.62 134.8 ± 19.19 123.9 ± 17.02 120.5 ± 17.01
01 132.1 ± 17.41 131.3 ± 18.35 126.3 ± 19.52 121.4 ± 17.23
02 131.2 ± 17.05 131.8 ± 19.23 126.4 ± 20.20 119.0 ± 15.77
03 131.0 ± 16.99 130.5 ± 18.45 125.4 ± 18.76 120.3 ± 16.88
04 132.0 ± 17.24 131.6 ± 19.39 122.8 ± 17.53 120.3 ± 16.77
05 134.3 ± 16.72 134.5 ± 19.34 126.4 ± 18.51 125.3 ± 16.89
06 138.0 ± 17.91 138.1 ± 19.87 127.1 ± 18.78 126.9 ± 16.26
07 143.6 ± 18.13 144.7 ± 20.76 130.4 ± 18.26 129.5 ± 17.06
08 149.0 ± 17.57 149.5 ± 20.70 135.3 ± 18.18 133.8 ± 16.27
09 151.7 ± 16.22 151.6 ± 19.97 140.7 ± 17.88 139.8 ± 17.80
24-h mean 146.2 ± 19.37 146.6 ± 22.86 128.3 ± 18.72 127.9 ± 17.95
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important reason why some b-blockers that are efficacious
as once-daily treatments for uncomplicated hypertension
need to be administered twice daily in patients with
ischemic heart disease. With regard to isolated blood
pressure lowering, it would appear to be of value for a drug
to have a pronounced effect during the early and mid-
daytime to counteract the blood pressure-raising effects of
daytime activities. Two related factors may, however,
increase the risk of adverse reactions: (1) associated b-
receptor-dependent adverse reactions, such as bradycardia,
can contribute to symptoms such as dizziness, fatigue, and
syncope; and (2) to achieve a 24-h effect with once-daily
dosing, higher doses are required, with the potential for
excess effects in the hours following administration. The
possibility of bisoprolol being associated with these nega-
tive effects might be suggested by results from the CIBIS-
ELD trial, where dose escalation is reported to have been
hampered by bradycardia [22, 23].
Various measures based on ABPM, such as the trough-
to-peak ratio and smoothness index, have been suggested
as a means to assess sufficient blood pressure-lowering
effects over the full 24-h dose interval. These single-item
variables appear to have lost much of their attractiveness
because of the undesirable properties inherent in ABPM
[24]. Some of these can be appreciated through the present
simulation. Despite a crossover model and a fairly large
study emulation, some time point recordings fall outside
the expected range, which, in a real study, can—depending
on when the random outlier occurs—have important effects
on the interpretation of the results.
It has been suggested that smoothing by combination
of measurements over several hours should be employed
to mitigate these kinds of outliers [2, 4]. That approach,
however, has the significant drawback of reducing the
information on the temporal effects of the drug under
investigation. Alternatively, the number of pressure
recordings per hour can be increased to allow for
smoothed hourly values. This modality runs the risk of
disturbing the diurnal blood pressure pattern of patients,
particularly during the night, as the repeated cuff
Fig. 2 Simulated systolic blood
pressure (bpsys) values for
bisoprolol and metoprolol
(mean and individual).
a Simulation of bisoprolol bpsys
by subject and time of day
(hours). b Simulation of
metoprolol bpsys by subject and
time of day (hours)
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inflations may interfere with rest and sleep. The likely
outcome is elevated pressures due to discomfort from the
inflations.
A second consequence of the variance of ABPM
recordings is shown by the bootstrapping model. Both the
overall between-groups effect, as well as the time point
Table 2 Estimates of changes
in systolic blood pressure
(Dbpsys) values
Bisoprolol versus baseline Metoprolol versus bisoprolol
Time of day
(hours)
Dbpsys 95 % confidence limit Time of day
(hours)
Dbpsys 95 % confidence limit
Lower Upper Lower Upper
11 -4.1 -6.1 -2.1 11 2.1 -0.7 4.8
12 -4.7 -7.2 -2.2 12 4.0 0.5 7.5
13 -6.1 -8.8 -3.4 13 1.2 -2.6 5.0
14 -8.9 -11.7 -6.0 14 3.8 -0.2 7.9
15 -4.5 -7.4 -1.6 15 -1.3 -5.4 2.8
16 -4.9 -7.9 -1.9 16 -2.7 -6.9 1.4
17 -4.4 -7.4 -1.4 17 -1.1 -5.3 3.1
18 -2.4 -5.4 0.6 18 -7.1 -11.3 -2.9
19 -3.5 -6.5 -0.4 19 -5.3 -9.6 -1.1
20 -4.8 -7.8 -1.8 20 -3.2 -7.4 1.1
21 -7.0 -10.0 -4.0 21 -2.5 -6.8 1.8
22 -8.7 -11.7 -5.6 22 -2.4 -6.7 1.9
23 -9.3 -12.4 -6.3 23 -3.0 -7.2 1.3
00 -9.4 -12.4 -6.4 00 -6.1 -10.4 -1.9
01 -7.1 -10.1 -4.0 01 -7.6 -11.9 -3.3
02 -6.9 -10.0 -3.9 02 -10.1 -14.4 -5.8
03 -7.9 -11.0 -4.9 03 -7.8 -12.1 -3.5
04 -10.6 -13.6 -7.6 04 -5.2 -9.5 -0.9
05 -7.0 -10.0 -4.0 05 -3.7 -8.0 0.5
06 -6.3 -9.3 -3.2 06 -2.9 -7.2 1.3
07 -2.9 -5.9 0.1 07 -3.6 -7.9 0.7
08 1.9 -1.1 4.9 08 -4.2 -8.4 0.1
09 7.3 4.3 10.4 09 -3.6 -7.9 0.7
Baseline 133.4 131.2 135.5
Fig. 3 Plasma concentrations at
steady state over the 24-h dose
interval: bisoprolol and
metoprolol succinate
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estimates, vary over wide ranges, indicating the need for
large sample sizes if robust comparisons between active
substances are to be obtained.
An important contributor to the potential issues with
ABPM can be seen from simulations of individual subjects’
blood pressures. Some values are clinically unlikely but are
not physiologic impossibilities. These outlier results will,
in most instances, have to be included in the analyses,
despite being unreasonable and heavily contributing to the
error margins.
Apart from not being a prospective clinical trial, this
simulation has some shortcomings that need to be taken
into consideration. No raw data were available for biso-
prolol, and no major ABPM study has been conducted with
metoprolol CR/ZOK. This necessitated the use of summary
data for simulation, which is the common situation in many
simulations. However, blood pressure has a well described
distribution, and the use of individual raw data as seeds in
the data generation is believed to have provided sufficient
background for the generation of sufficiently representative
data values. The reported variances generally reflected
office blood pressure recordings or smoothed values from
ABPM. As these variance values were smaller than those
observed in ABPM of untreated patients, the variances
were expanded by normally distributed random values to
better emulate the distribution of observed ABPM. Finally,
the validation bootstrap used subsamples and not full sets.
This was done to make the computational process more
manageable and is not believed to have had a significant
impact on the reliability of the validation.
5 Conclusion
In this simulation study of the effects of bisoprolol and
metoprolol CR/ZOK on 24-h bpsys, the mean effects
were the same, while the diurnal patterns differed
between the two treatments. This difference may be of
clinical relevance, given the recognized diurnal pattern
of CV events.
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